OCX future rides on Lung Cancer diagnostic adoption.
At PPS > 1.30 MC ~ 96M
6/29 DetermaDx failed the final clinical test in a series of much hyped validation procedures.
2 viable products remain:
* DetermaRx diagnoses lung cancer using a simple blood test. It has already been approved by Centers for Medicare/Medicaid Services (cms) CMS reimburses 70% of approved cost. Earning potential could be up to $500M pa. Conservatively, 2021 revenue is estimated to exceed $30M
* DetermaI/O identifies the approximate 30% of cancer patients who are eligible for immune therapy. It is presently used in research settings.
As of 4/31/20 Cash = 27.6M Burn rate is expected to be ~6.0M per Q for remainder or 2020.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.